Efficacy and safety of direct oral anticoagulants in the treatment of left ventricular thrombus after acute anterior myocardial infarction in patients who underwent percutaneous coronary intervention.

Abstract

To explore treatment with direct oral anticoagulants (DOACs) in left ventricular thrombus (LVT) after ST-segment elevation myocardial infarction (STEMI) in patients who underwent percutaneous coronary intervention (PCI). Contemporary data regarding using DOACs for LVT after STEMI patients who underwent PCI is limited. To investigate the efficacy and safety of DOACs on treatment of LVT post STEMI and PCI. This retrospective study enrolled patients with LVT post STEMI and PCI within 1month from onset who received warfarin or DOACs at discharge. Primary endpoint was LVT resolution. Secondary endpoints were major adverse cardiovascular events (MACEs), including death, stroke, systemic embolism (SE), myocardial infarction (MI) and major or minor bleeding. A total of 128 consecutive patients were recruited, of which 72 received warfarin and 56 DOACs [48 on rivaroxaban and 8 on dabigatran]. Rate of LVT resolution was higher within 1 month in the DOAC group than warfarin (26.8% vs 11.1%; p=0.022) (Kaplan-Meier estimates, p=0.002).No significant differences were found at 3 months ( p=0.246), 6 months (p=0.201), 9 months (p=0.171) and 12 months (p=0.442). No patients treated with DOACs had major bleeding, while two patients with warfarin had upper gastrointestinal bleeding (0 vs 2 (2.8%); p=0.209). No death or SE was occurred. No significant differences on secondary endpoints were found in both the groups, including stroke, MI, minor bleeding and all bleeding events. DOACs appears to be a suitable alternative to warfarin for the management of LVT post STEMI, especially in patients who are intolerant to warfarin.